Earnings Call · Q2 FY2024·2024-08-15

Q2 24EPS +20.75%·Rev n/aQ1 24EPS +56.16%·Rev n/aQ4 23EPS +10.00%·Rev n/aQ3 23EPS +19.78%·Rev n/a⚠ consensus missing

Arcutis Biotherapeutics, Inc. ARQT

Latha Vairavan — Investor Relations

Frank Watanabe — President and CEO

Todd Edwards — Chief Commercial Officer

Patrick Burnett — Chief Medical Officer

David Topper — Chief Financial Officer

−11.3%1d on move date−13.0% vs SPY3d−9.7%5d−12.9%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ARQT calls or request research access.

More ARQT calls Browse calls Request research access